Leaflet ENZALUTAMIDA RHEI 40mg soft capsules

Product code:
W71152001
Quantity:
28
Indicated for:
prostate cancer
Route of administration:
oral
Substance:
enzalutamide (antiandrogen)
ATC
L02BB04 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-androgens
Enzalutamide is a medication used to treat advanced or metastatic prostate cancer. It works by blocking the effect of androgens, hormones that stimulate the growth of prostate cancer cells. Enzalutamide is usually taken as tablets, as directed by the oncologist.

Treatment with enzalutamide requires careful monitoring, as side effects or interactions with other medications may occur. It is important for patients to follow the treatment schedule and inform the doctor about any new or unusual symptoms.

Side effects may include fatigue, high blood pressure, headaches, sleep disturbances, diarrhea, or loss of appetite. In rare cases, seizures or severe allergic reactions may occur.

Enzalutamide is an effective option for patients with advanced prostate cancer, but it requires constant medical supervision to ensure the effectiveness and safety of the treatment. Collaboration with the medical team is essential for therapy success.

General data about ENZALUTAMIDA RHEI 40mg

Substance:
enzalutamide
Date of latest medicines list:
01-07-2025
Product code:
W71152001
Concentration:
40mg
Pharmaceutical form:
soft capsules
Quantity:
28
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PHARMADOX HEALTHCARE LIMITED - MALTA
Holder:
RHEI LIFE D.O.O. - SLOVENIA
Number:
16043/2025/01
Shelf life:
3 years

Pharmaceutical forms available for enzalutamide

Concentrations available for enzalutamide

  • 160mg
  • 40mg
  • 80mg